Verici Dx PLC Two key patents granted in the US (3688S)
09 March 2023 - 6:00PM
UK Regulatory
TIDMVRCI
RNS Number : 3688S
Verici Dx PLC
09 March 2023
Verici Dx plc
("Verici Dx" or the "Company")
Two key patents for Tutivia(TM) and Clarava(TM) granted in the
United States
Intellectual property portfolio strengthened
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that it has been
granted two key patents in the United States that support and
protect the Company's core technologies in RNA signature biomarker
tests used for assessment of the prognostic risk pre-transplant (
Clarava(TM) ) and post-transplant ( Tutivia(TM) ) of acute kidney
transplant rejection.
The patents cover broad molecular methods for predicting and
diagnosing subclinical and clinical acute rejection, both pre- and
post- kidney transplant by algorithmic analysis of gene sets and
underpin both of Verici Dx's lead products, Tutivia(TM) and
Clarava(TM), and provide protection until 2036 and 2039
respectively. The patents underpinning Tutivia(TM) have also been
previously granted in Europe, China and Australia.
These products use a weighted pattern of RNA biomarkers
(signature) to assess the risk of rejection by the kidney
transplant recipient and to assess rejection earlier and more
reliably than other currently available methods. Verici Dx
continues to file additional patents reflecting novel refinements
to its predictive RNA signatures and methodologies driven by
advanced machine learning techniques.
The protection of the Company's intellectual property is
fundamental to its strategy of amassing full transcriptomic data
from the biological systems and interactions associated with
transplant rejection and, over the longer term, informing
transplant analysis in other organs and in the broader field of
immune-mediated diseases.
Sara Barrington, CEO of Verici Dx, said:
" Clarava(TM) and Tutivia(TM) address a significant unmet need
and seek to improve outcomes for kidney transplant patients, by
providing early, actionable information for clinicians to inform
treatment plans. These significant new patents bolster our
intellectual property portfolio and protect our proprietary methods
of predicting and diagnosing sub-clinical and clinical acute kidney
rejection."
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Tel: +44 20 7496 3000
Adviser & Broker)
Aubrey Powell / Sam Butcher
Walbrook PR Limited Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Stephanie Cuthbert Mob: +44 7980 541 893 / +44 7796
/ 794 663 /
Sam Allen 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of
leading-edge tests forming a kidney transplant platform for
personalised patient and organ response risk to assist clinicians
in medical management for improved patient outcomes. The underlying
technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, rejection and graft failure
from pre-transplant to late stage. The Company also has a mission
to accelerate the pace of innovation by research using the fully
characterised data from the underlying technology and collaboration
with medical device, biopharmaceutical and data science
partners.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
The two lead products are Clarava(TM), a pre-transplant
prognosis test for the risk of early acute rejection, and
Tutivia(TM), a post-transplant test focused upon acute cellular
rejection, including sub-clinical rejection. These products seek to
measure how a patient is likely to respond, and is responding, to a
kidney transplant. These products are underpinned by extensive
patented and published scientific research from the leading Mount
Sinai Medical Center, for which the Company holds an exclusive
worldwide licence.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDDGDXGSGDGXI
(END) Dow Jones Newswires
March 09, 2023 02:00 ET (07:00 GMT)
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Feb 2024 to Feb 2025
